One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Oligonucleotide Synthesis Market

オリゴヌクレオチド合成市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2022年


[ 英語タイトル ] Oligonucleotide Synthesis Market by Product (Primer, Probe, Linker, Adaptor, Custom, Reagent, Equipment), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Academic, Pharmaceutical, Biotechnology) - Global Forecast to 2022


Product Code : MNMHC00109346
Survey : MarketsandMarkets
Publish On : July, 2021
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD5650 / Question Form
5 User USD6650 / Question Form
Enterprise User USD10000 / Question Form

[Report Description]

“The global oligonucleotide synthesis market projected to grow at a CAGR of 10.9%.”
The global oligonucleotide synthesis market is expected to reach USD 2.46 billion by 2022 from USD 1.47 billion in 2017 at a CAGR of 10.9%. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.
Growth in this market is mainly driven the increasing R&D expenditure by pharmaceutical and biotechnology companies, rising demand for synthesized oligonucleotides from the growing field of molecular diagnostics, rising venture capital investments, and increasing demand for synthetic genes. However, the price erosion of synthesized oligos and lack of regulations for therapeutic oligos are some factors that may hinder the growth of this market.

“Synthesized oligonucleotides are expected to grow at the highest CAGR during the forecast period.”
Based on product, the market is segmented into synthesized oligonucleotides, reagents, and equipment. The synthesized oligonucleotides segment is expected to grow at the highest CAGR during the forecast period The increasing number of applications of synthesized oligonucleotides in research, diagnostics, and therapeutics is a key market driver in this segment. The rising availability and demand for custom oligos also contribute to the growth of the synthesized oligonucleotides market.


“The research segment is expected to hold the largest share of the market in 2017.”
Based on application, the market is segmented into research, diagnostics, and therapeutics. The research segment is estimated to hold the largest share of the oligonucleotide synthesis market in 2017. The market growth for research applications is mainly driven by the developments in the fields of gene synthesis and NGS. Oligos are widely used in technologies such as PCR, qPCR, gene synthesis, isothermal nucleic acid amplification technology (INAAT), microarray, hybridization, DNA sequencing, and next-generation sequencing (NGS).


“Academic research institutes are expected to dominate the market during the forecast period.”
Based on end user, the market is segmented into academic research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and other end users. The academic research institutes segment is expected to dominate the market during the forecast period. With the increasing funding pouring into institutes to conduct research, the demand for oligonucleotides is bound to increase. To meet this need, companies are launching products and entering into agreements with different research institutes to supply oligonucleotides for research purposes. For instance, in August 2015, Eurofins Genomics launched NGS tests for the identification of non-targeted microorganisms, including 16S Microbiome Profiling for academia and research.



“APAC to witness the highest growth during the forecast period.”

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. This can be attributed to factors such as the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the APAC region. The increasing focus of prominent players on APAC is also supporting market growth in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 36%; Tier 2 - 46%; Tier 3 - 18%.
• By Designation: C-level- 26%; D-level- 45%; Others- 29%.
• By Region: North America-41%; Europe-31%; Asia Pacific-20%; Latin America- 5%, Middle East and Africa-3%

List of companies profiled in the report
• Agilent Technologies (US)
• ATDBio (UK)
• Bio-Synthesis (US)
• BioAutomation (US)
• LGC Biosearch Technologies (US)
• Eurofins Genomics (Germany)
• Eurogentec (Belgium)
• GeneDesign (Japan)
• GE Healthcare (US)
• GenScript (US)
• Integrated DNA Technologies (IDT) (US)
• Nitto Denko Avecia (US)
• Thermo Fisher Scientific (US)
• TriLink Biotechnologies (US)
• Sigma-Aldrich Corporation (Sigma-Aldrich) (US) (part of Merck KGAA (Germany)
Research Coverage:
The report provides an overview of the oligonucleotide synthesis market. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall oligonucleotide synthesis market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 DEFINITION 22
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.3.2 YEARS CONSIDERED FOR THE STUDY 24
1.4 CURRENCY 24
1.5 LIMITATIONS 24
1.6 STAKEHOLDERS 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.2 SECONDARY DATA 27
2.2.1 SECONDARY SOURCES 27
2.3 PRIMARY DATA 28
2.3.1 KEY DATA FROM PRIMARY SOURCES 28
2.3.2 KEY INDUSTRY INSIGHTS 29
2.4 MARKET SIZE ESTIMATION 30
2.4.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 30
2.4.2 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 31
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 32
2.6 ASSUMPTIONS FOR THE STUDY 33
3 EXECUTIVE SUMMARY 34
4 PREMIUM INSIGHTS 39
4.1 ATTRACTIVE OPPORTUNITIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET 39
4.2 OLIGONUCLEOTIDES SYNTHESIS MARKET, BY SYNTHESIZED OLIGONUCLEOTIDES PRODUCTS 40
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY SYNTHESIZED OLIGONUCLEOTIDES TYPE 40
4.4 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY RESEARCH APPLICATION AND COUNTRY 41
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY THERAPEUTIC APPLICATION 42
4.6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 43
4.7 GEOGRAPHIC SNAPSHOT: OLIGONUCLEOTIDE SYNTHESIS MARKET 44

5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DRIVERS 46
5.2.1 INCREASING USE OF SYNTHESIZED OLIGONUCLEOTIDES IN MOLECULAR DIAGNOSTICS AND CLINICAL APPLICATIONS 46
5.2.2 INCREASING GOVERNMENT INVESTMENTS AND R&D EXPENDITURE IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 47
5.2.3 RISE IN VENTURE CAPITAL INVESTMENTS 48
5.3 MARKET RESTRAINTS 48
5.3.1 PRICE EROSION OF SYNTHESIZED OLIGONUCLEOTIDES 48
5.3.2 LACK OF A UNIFIED SET OF REGULATIONS FOR THERAPEUTIC OLIGONUCLEOTIDES 48
5.4 MARKET OPPORTUNITIES 49
5.4.1 EMERGING ASIAN MARKETS 49
5.5 MARKET CHALLENGES 50
5.5.1 LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES 50
5.5.2 DELIVERY OF OLIGONUCLEOTIDE DRUGS TO SPECIFIC TARGETS 50
5.6 INDUSTRY TRENDS 51
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 52
6.1 INTRODUCTION 53
6.2 SYNTHESIZED OLIGONUCLEOTIDES 54
6.2.1 BY PRODUCT 57
6.2.1.1 Primers 57
6.2.1.2 Probes 60
6.2.1.3 Large-scale synthesis oligonucleotides 63
6.2.1.4 Intermediate-scale synthesis oligonucleotides 65
6.2.1.5 Linkers & Adaptors 68
6.2.2 BY TYPE 70
6.2.2.1 Custom oligonucleotides 71
6.2.2.2 Pre-designed oligonucleotides 74
6.3 REAGENTS 76
6.4 EQUIPMENT 79
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 82
7.1 INTRODUCTION 83
7.2 RESEARCH 84
7.2.1 PCR 87
7.2.2 QPCR 89
7.2.3 SEQUENCING 91
7.2.4 GENE SYNTHESIS 93
7.2.5 OTHER RESEARCH APPLICATIONS 96
7.3 DIAGNOSTICS 98
7.4 THERAPEUTICS 101
7.4.1 RNAI 104
7.4.2 NUCLEIC ACID APTAMERS 107
7.4.3 DNA/ANTISENSE OLIGONUCLEOTIDES 109
7.4.4 IMMUNOTHERAPY APPLICATIONS 112
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 115
8.1 INTRODUCTION 116
8.2 ACADEMIC RESEARCH INSTITUTES 117
8.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 120
8.4 DIAGNOSTIC LABORATORIES 123
8.5 OTHER END USERS 125
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 128
9.1 INTRODUCTION 129
9.2 NORTH AMERICA 130
9.2.1 US 135
9.2.2 CANADA 139
9.3 EUROPE 143
9.3.1 GERMANY 149
9.3.2 FRANCE 153
9.3.3 UK 157
9.3.4 REST OF EUROPE (ROE) 161
9.4 ASIA PACIFIC (APAC) 166
9.4.1 CHINA 171
9.4.2 JAPAN 175
9.4.3 INDIA 179
9.4.4 REST OF ASIA PACIFIC (ROAPAC) 183
9.5 LATIN AMERICA 188
9.5.1 BRAZIL 193
9.5.2 MEXICO 194
9.5.3 REST OF LATIN AMERICA 196
9.6 MIDDLE EAST & AFRICA 198
10 COMPETITIVE LANDSCAPE 203
10.1 OVERVIEW 203
10.2 MARKET SHARE ANALYSIS 204
10.3 COMPETITIVE SCENARIO 207
10.3.1 PARTNERSHIPS, AGREEMENTS, CONTRACTS, AND COLLABORATIONS 207
10.3.2 PRODUCT LAUNCHES, UPGRADES, AND APPROVALS 207
10.3.3 EXPANSIONS 208
10.3.4 ACQUISITIONS 209
11 COMPANY PROFILES 210
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View)*
11.1 INTEGRATED DNA TECHNOLOGIES 210
11.2 MERCK KGAA 216
11.3 EUROFINS GENOMICS 222
11.4 THERMO FISHER SCIENTIFIC 226
11.5 BIOAUTOMATION 230
11.6 AGILENT TECHNOLOGIES 233
11.7 EUROGENTEC 241
11.8 GE HEALTHCARE 245
11.9 LGC BIOSEARCH TECHNOLOGIES 249
11.10 NITTO DENKO AVECIA 251
11.11 GENSCRIPT 254
11.12 GENEDESIGN (PART OF AJINOMOTO) 257
11.13 TRILINK BIOTECHNOLOGIES (PART OF MARAVAI LIFESCIENCES) 259
11.14 BIO-SYNTHESIS 261
11.15 ATDBIO 263
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View might not be captured in case of unlisted companies.
12 APPENDIX 264
12.1 INSIGHTS FROM INDUSTRY EXPERTS 264
12.2 DISCUSSION GUIDE 265
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 268
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 270
12.5 AVAILABLE CUSTOMIZATIONS 270
12.6 RELATED REPORTS 271
12.7 AUTHOR DETAILS 272

 

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+